<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204652">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000320</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-10068-1</org_study_id>
    <secondary_id>R01-10068-1</secondary_id>
    <nct_id>NCT00000320</nct_id>
  </id_info>
  <brief_title>Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1</brief_title>
  <official_title>Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare subject response to liquid vs. tablet formulations,
      to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to
      evaluate if dose response curve for tablet is equal to liquid form.&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1) Compare subjects response to liquid vs tablet formulation 2) Assess bioequivalency of
      liquid vs tablet 3)Compare subject preference 4) Evaluate if dose response curve for tablet
      = to liquid form
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">August 1999</completion_date>
  <primary_completion_date type="Actual">August 1999</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>blood level</measure>
    <time_frame>across study duration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>drug use</measure>
    <time_frame>across study duration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>craving</measure>
    <time_frame>across study duration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>withdrawal symptoms</measure>
    <time_frame>across study duration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1; liquid formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liquid formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2; tablet formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablet formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine formulation: liquid vs. tablet</intervention_name>
    <description>random assignment to liquid buprenorphine or tablet buprenorphine</description>
    <arm_group_label>1; liquid formulation</arm_group_label>
    <arm_group_label>2; tablet formulation</arm_group_label>
    <other_name>Subutex</other_name>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        M/F ages 18-65. Meet DMS-IV criteria for opiate dependence. Agree to conditions of the
        study and sign informed consent.

        Exclusion Criteria:

        Pregnant or nursing women. Acute medical condition that would interfere with study
        participation or put safety of subjects in jeopardy. Current daily use of
        anti-convulsants, antabuse or neuroleptics. DSM-IV diagnosis of ETOH or sedative/hypnotics
        dependence.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <lastchanged_date>January 5, 2009</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <name_title>Walter Ling, M.D.</name_title>
    <organization>Friends Research Institute</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
